Quantcast
Last updated on April 18, 2014 at 5:30 EDT

Latest Syndax Pharmaceuticals Inc. Stories

2014-03-27 20:21:46

WALTHAM, Mass., March 27, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Syndax. The number of shares to be offered and the price range for the offering have not yet been determined. Deutsche Bank...

2014-03-20 23:22:02

Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in its latest trial, E2112. Philadelphia, PA, and Waltham, MA (PRWEB) March 20, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Syndax Pharmaceuticals, Inc., announced today that patient recruitment has begun for E2112, a randomized phase III clinical trial of Syndax’s entinostat in treatment of patients with advanced breast cancer. The...

2014-02-13 08:30:49

WALTHAM, Mass., Feb. 13, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., today announced that the Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) has reached a special protocol assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the planned pivotal Phase 3 trial of entinostat in patients with advanced breast cancer. The Phase 3 trial, expected to begin in the first half of this year, is intended to evaluate...

2014-02-03 08:27:30

WALTHAM, Mass., Feb. 3, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., today announced the appointment of distinguished breast cancer specialist, George W. Sledge, Jr., M.D., to its board of directors as an independent director. Dr. Sledge is currently professor and chief of medical oncology at Stanford University Medical Center. He specializes in the study and treatment of breast cancer and directed the first large, nationwide study on the use of paclitaxel to treat advanced...

2014-01-23 08:30:59

WALTHAM, Mass., Jan. 23, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. today announced the appointment of Richard P. Shea to its board of directors as an independent director and chairman of the audit committee. Mr. Shea is an experienced biotechnology executive with wide ranging experience in finance and operations as well as managing venture financings, initial public offerings, secondary offerings and mergers and acquisitions. Mr. Shea is currently senior vice president and...

2013-11-01 08:26:50

WALTHAM, Mass., Nov. 1, 2013 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. today announced the promotion of John S. Pallies to chief financial officer from vice president, finance and administration, and co-founder Peter Ordentlich, Ph.D., to chief technology officer from vice president, translational medicine. Both appointments are effective Nov.1, 2013. "These promotions are recognition of the exceptional work John and Peter have done helping Syndax develop to the point of being...

2013-10-11 08:23:53

WALTHAM, Mass., Oct. 11, 2013 /PRNewswire/ -- Syndax Pharmaceuticals Inc. today announced the appointment of Steven M. Fruchtman, M.D., a hematologist/oncologist with extensive experience in early and late-stage drug development with biopharmaceutical companies and in clinical practice, as chief medical officer. Dr. Fruchtman will oversee clinical development programs for entinostat in breast, lung and other malignancies. This will include the company's work with ECOG-ACRIN Cancer...

2013-09-11 08:27:59

Epigenetic Mechanism with Potential to Reverse Resistance to Hormonal Therapy in Patients with Limited Treatment Options WALTHAM, Mass., Sept. 11, 2013 /PRNewswire/ -- Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has...

2013-09-04 08:31:53

Agreement Includes a Joint Development Committee and Eddingpharm's Participation in Global Registration Trials WALTHAM, Mass., Sept. 4, 2013 /PRNewswire/ -- Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers and Eddingpharm, a leading specialty pharmaceutical company in China, entered into a licensing, development and commercialization agreement that gives Eddingpharm exclusive rights to develop, market and sell entinostat in China and...

2013-08-27 08:27:31

Company Prepares for Pivotal Phase 3 Study of Entinostat, Most Advanced HDAC Inhibitor in Development for ER+ Metastatic Breast Cancer WALTHAM, Mass., Aug. 27, 2013 /PRNewswire/ -- Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers, today announced it has secured a $26.6 million Series B financing. Participating investors included Domain Associates, MPM Capital, Forward Ventures and RusnanoMedInvest (RMI). Syndax plans to use the...